246 related articles for article (PubMed ID: 15841467)
1. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
2. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
4. Age-related changes in the protein and mRNA levels of CYP2E1 and CYP3A isoforms as well as in their hepatic activities in Wistar rats. What role for oxidative stress?
Wauthier V; Verbeeck RK; Buc Calderon P
Arch Toxicol; 2004 Mar; 78(3):131-8. PubMed ID: 14600803
[TBL] [Abstract][Full Text] [Related]
5. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
6. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
7. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C.
Haufroid V; Ligocka D; Wallemacq P; Lison D; Horsmans Y
Toxicol Lett; 2005 Jan; 155(1):171-7. PubMed ID: 15585372
[TBL] [Abstract][Full Text] [Related]
10. The effect of hormone replacement therapy on CYP3A activity.
Gorski JC; Wang Z; Haehner-Daniels BD; Wrighton SA; Hall SD
Clin Pharmacol Ther; 2000 Oct; 68(4):412-7. PubMed ID: 11061581
[TBL] [Abstract][Full Text] [Related]
11. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
12. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
13. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
15. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
16. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
18. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Emery MG; Fisher JM; Chien JY; Kharasch ED; Dellinger EP; Kowdley KV; Thummel KE
Hepatology; 2003 Aug; 38(2):428-35. PubMed ID: 12883487
[TBL] [Abstract][Full Text] [Related]
19. Posttranscriptional elevation of cytochrome P450 3A expression.
Zangar RC; Hernandez M; Novak RF
Biochem Biophys Res Commun; 1997 Feb; 231(1):203-5. PubMed ID: 9070249
[TBL] [Abstract][Full Text] [Related]
20. Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2008 May; 91(5):733-8. PubMed ID: 18672640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]